ASTH

Astrana Health, Inc. (ASTH) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Astrana Health, Inc. is a physician-centric, technology-enabled healthcare management company operating through three segments: Care Partners, Care Delivery, and Care Enablement. As of June 30, 2026, the Company managed approximately 1.5 million patients across 29 risk-bearing organizations. The reporting period includes the full impact of the Prospect Medical Holdings acquisition, which closed on July 1, 2025.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 49% quarter-over-quarter and 52% year-to-date, primarily driven by the Prospect acquisition (contributing $281.5 million in Q2 and $581.6 million YTD) and increased capitation from members transitioning to full risk.
• Profitability: Net income attributable to Astrana increased 109% in Q2 and 112% YTD. Operating income rose 69% in Q2 to $34.3 million.
• Expense Increases: Cost of services increased 51% in Q2, largely due to the acquisition and higher medical costs. Depreciation and amortization surged 125% in Q2 due to intangible assets from the Prospect deal.
• Interest Expense: Interest expense increased 117% in Q2 to $16.0 million due to higher debt levels ($948.3 million) utilized to finance the acquisition, partially offset by lower interest rates (5.64% vs 6.08% in prior year).
• Segment Performance:
  • Care Partners: Revenue up 48%, but operating income down 14% due to higher claims expense.
  • Care Delivery: Revenue up 95%, but operating loss widened to $3.0 million due to growth investments.
  • Care Enablement: Revenue up 109% and operating income up significantly to $16.4 million, driven by management fees and new contracts.

Guidance, Outlook, Risks, and Contingencies

• Internal Controls: Management identified a material weakness in internal control over financial reporting related to the accounting for business combinations. This weakness was not remediated as of June 30, 2026, rendering disclosure controls and procedures ineffective. Remediation is ongoing.
• Liquidity: The Company maintains $400.8 million in cash and $258.0 million in available revolver capacity. Management believes liquidity is sufficient for the next 12 months.
• Legal Proceedings: A significant arbitration with a provider (CFC HP) was settled in February 2026. The Company paid $13.0 million in total ($12.0 million in 2025, $1.0 million in 2026) and is seeking reimbursement from escrow funds, though no recovery was recorded as of June 30, 2026.
• Regulatory Risks: The Company faces complex regulations regarding Medicare, Medicaid, and state-specific managed health care laws (e.g., DMHC requirements for tangible net equity and cash-to-claims ratios).
• Debt Structure: The Company has a Second Amended and Restated Credit Facility with a maturity date of February 26, 2030. An interest rate swap agreement covers $200 million of debt at a fixed rate of 3.179%.

Investor Verification Checklist

• Remediation of Material Weakness: Verify the specific steps and timeline management has outlined to remediate the internal control weakness regarding business combination accounting.
• Receivable Allowances: Review the $1.3 million allowance recorded against receivables in the Care Partners segment that management plans to recover from the payer.
• Escrow Recovery: Monitor the status of the claim for reimbursement of the $13.0 million CFC HP settlement from the acquisition escrow account.
• Debt Covenants: Confirm compliance with leverage ratios and tangible net equity requirements under the credit facility and DMHC regulations.
• Non-GAAP Reconciliations: Scrutinize the "Other, net" adjustments in the Adjusted EBITDA reconciliation, which included $4.8 million in Q2 for legal matters and integration costs.